Collegium Pharmaceutical (COLL) Surged Following Record Quarterly Results

1 hour ago 5

Soumya Eswaran

Tue, March 10, 2026 astatine 8:04 AM CDT 2 min read

Third Avenue Management, a New York City-based concern firm, published its fourth-quarter 2025 capitalist missive for the “Third Avenue Small-Cap Value Fund. " A transcript of the missive is disposable for download here. In the quarter, the Fund returned 4.62%, outperforming the MSCI USA Small-Cap Value Index (the “Index”), which gained 3.13%. For the twelvemonth 2025, the Fund delivered a 14.04% return, surpassing the 10.80% instrumentality of the index. The Fund chiefly invests successful publically traded companies with boards of directors, sometimes controlled by individuals oregon families, and absorption teams that run independently from the Fund. Reviewing 2025, the steadfast is pleased with the Fund's performance, operational success, and shareholder worth creation, and is optimistic astir 2026. Please reappraisal the Fund’s apical 5 holdings to summation insights into their cardinal selections for 2025.

In its fourth-quarter 2025 capitalist letter, Third Avenue Small-Cap Value Fund highlighted Collegium Pharmaceutical, Inc. (NASDAQ:COLL) arsenic 1 of its starring contributors. Collegium Pharmaceutical, Inc. (NASDAQ:COLL) is simply a specialty pharmaceutical institution that focuses connected processing medicines for symptom management. On March 09, 2026, Collegium Pharmaceutical, Inc. (NASDAQ:COLL) banal closed astatine $37.27 per share. One-month instrumentality of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) was -20.28%, and its shares gained 24.27% implicit the past 52 weeks. Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has a marketplace capitalization of $1.183 billion.

Third Avenue Small-Cap Value Fund stated the pursuing regarding Collegium Pharmaceutical, Inc. (NASDAQ:COLL) successful its 4th fourth 2025 capitalist letter:

"U.S. symptom medicine specialist, Collegium Pharmaceutical, Inc. (NASDAQ:COLL), besides generated a beardown show publication successful the 4th aft producing grounds quarterly gross and disclosing improved operating income guidance and a caller stock repurchase authorization."

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) is not connected our database of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 34 hedge money portfolios held Collegium Pharmaceutical, Inc. (NASDAQ:COLL) astatine the extremity of the 4th quarter, up from 27 successful the erstwhile quarter. While we admit the imaginable of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

Read Entire Article